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Abstract. Technetium-99m hexakis-2-methoxyisobutyl- 
isonitrile (MIBI), 99mTc-tetrofosmin and 99mTc-Q12 
were all introduced for myocardial imaging but found 
additional applications as they are taken up by different 
tumours, enabling imaging of these lesions in patients. 
The aim of this study was to compare the uptake charac- 
teristics of these compounds in vitro in the human ade- 
nocarcinoma breast cell lines MCF-7 and ZR-75. It was 
shown that 99mTc-MIBI had the highest cellular uptake 
(15.9%+_0.5% dose/mg protein after 60 min in MCF-7, 
and 14.2%+0.4% dose/mg protein in ZR-75), followed 
by 99mTc-tetrofosmin (6.8%_+0.6% dose/mg protein in 
MCF-7, and 8.2%+.0.2% dose/mg protein in ZR-75) and 
99mTc-Q12 (3.2%+.0.1% dose/mg protein in MCF-7, and 
3.5%+.0.3% dose/rag protein in ZR-75 cells). For all 
three compounds tenfold differences in specific activity 
did not influence total cell-associated radioactivity. Up- 
take of 99mTc-MIBI and 99mTc-tetrofosmin was obvious- 
ly lower at 4 ° C than at 37 ° C, whereas 99r~Tc-QI2 up- 
take showed only slight temperature dependence. When 
uptake was compared in cells grown to different cell 
densities (1 mg/ml cellular protein versus 0.3 mg/ml), no 
differences in uptake were detected when uptake was 
corrected for the amount of cellular protein present in 
the dishes. Furthermore, for all compounds it was shown 
that cellular radioactivity decreased rapidly after wash- 
ing. Apart from the differences in cellular uptake of the 
three compounds after 60 min, no differences in residual 
cellular radioactivity after washing were found between 
the different compounds when expressed as a percentage 
of their 60-min uptake, suggesting that the efflux process 
of the radiolabelled compounds was similar. The differ- 
ences in cell-associated activity after 60 min were thus 
presumably caused by differences in uptake. It was con- 
cluded that of the Tc-labelled compounds tested, 99mTC- 
MIBI had the highest cellular retention in both human 
breast umour cell lines. However, for imaging in vivo 
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not only radioactivity in the target organ is important, 
but also the ratio of radioactivity in the target versus that 
in the background. Therefore, further studies in vivo 
need to be performed to investigate which compound is 
the optimal imaging agent. 
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Introduction 
Technetium-99m hexakis-2-methoxyisobutylisonitrile 
(MIBI) is a 99mTc-labelled lipophilic cationic complex 
that has been used since 1984 for myocardial perfusion 
imaging [1, 2]. It quickly found other applications in the 
area of tumour imaging in cancer patients: Mtiller et al. 
described its uptake by pulmonary metastases of thyroid 
cancer [3], and since then, many groups have studied its 
uptake by, for example, bronchial carcinoma [4], osteosar- 
coma [5], parathyroid adenoma [6] and breast umours [7, 
8]. Furthermore, Piwnica-Worms et al. reported in 1992 
the important observation that 99mTc-MIBI is a ligand for 
P-glycoprotein (Pgp), the product of the human multidrug 
resistance gene (MDR1), which confers resistance to 
drugs by transporting cytotoxic agents out of cells [9]. 
Thus, this widely available radiopharmaceutical may be 
useful for imaging the Pgp status of tumours. However, 
the extensive hepatobiliary excretion of 99mTc-MIBI and 
its uptake in heart, liver, kidneys and total gastrointestinal 
tract [10] make imaging in the abdomen extremely diffi- 
cult, and it is therefore not an ideal imaging agent. 
99mTc-MIBI belongs to a class of compounds that 
have a core atom of radioactive technetium in their 
structures. Other compounds also introduced for myo- 
cardial perfusion imaging are: 99mTc-tetrofosmin, a lipo- 
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Fig. 1. Time course of cellular adioactivity, 
expressed as % dose/rag cellular protein, of 
99mTc-MIBI, 99mTc-tetrofosmin, 99mTc-Q12 
and 99rnTcO4 in a MCF-7 cells and b ZR-75 
cells, at both 37 ° C and 4 ° C 
philic diphosphine, and 99mTc-Q12, a mixed ligand com- 
plex of the "Q"-series of non-reducible Tc(III)cations. 
99mTc-tetrofosmin has also been reported to be suitable 
for clinical evaluation of breast tumours [11] and for 
functional imaging of multidrug resistance [12], and its 
pharmacokinetic advantages over 99mTc-MIBI for cardi- 
ac imaging [13] may also apply to tumour imaging. 
99mTc-Q12 is also a transport ligand recognized by the 
human MDR P-glycoprotein [14]. 
The purpose of this study was to compare the uptake 
characteristics of 99mTc-MIBI, 99mTc-tetrofosmin and 
99mTc-Q12 during 60 min in well-characterized in vitro 
tumour models: the human adenocarcinoma breast cell 
lines MCF-7 and ZR-75. 
Materials and methods 
Cell culture. The MCF-7 and ZR-75 cell lines were obtained from 
Dr. J.A. Foekens, Dr. Daniel den Hoed Cancer Centre, Rotterdam, 
The Netherlands, and grown in RPMI-1640 (phenolred-free, Gi- 
bco, Grand Island, N.Y.) medium (pH 7.5), supplemented with 24 
mM NaHCO 3, 2 mM glutamine, 10% heat-inactivated fetal calf 
serum (FCS), and 10 gg/ml insulin in 75 cm 2 flasks in a 5% CO~, 
37 ° C, humidified incubator. For ZR-75 cells, I nM 17[3-oestradiol 
was also added to the medium. Before the experiment, subconflu- 
ent cell cultures were trypsinized and transferred to six-well 
plates. Unless otherwise stated, cells in the six-well plates were 
used for the experiments after reaching confluency. 
Radiolabelling. MIBI (Dupont, Billerica, Mass.), tetrofosmin 
(Amersham International, Aylesbury, Buckinghamshire, UK) and 
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Fig. 2. Influence of specific activi- 
ty (185,555 or 1850 MBq/kit) on 
cellular adioactivity of 99mTc- 
MIBI, 99mTc-tetrofosmin a d 
99mTc-Q12 in a MCF-7 cells and 
b ZR-75 cells 
Q12 (Mallinckrodt Medical, Petten, The Netherlands) were la- 
belled according to the kit instructions; labelling efficiency was 
always greater than 95%. 1850 MBq 99mTc was added to each kit. 
In experiments dealing with the effects of specific activity, kits 
were radiolabelled by addition of 185,555 or 1850 MBq. 
Experimental design. Before the experiment, cells were washed 
and incubation was started by addition of 1 ml incubation medi- 
um/well (incubation medium is culture medium without FCS, but 
with 0.2% bovine serum albumin) with 97.5 kBq of either sub- 
stance (unless otherwise stated). 
Cells were incubated at 37 ° C for indicated periods of time. 
Cellular uptake was stopped by removing the incubation medium 
from the cells, washing with 2 ml ice-cold phosphate-buffered sa- 
line (PBS), and lysis of the cells in 1 ml 0.1 N NaOH. Removal of 
cellular radioactivity from the dish was more than 99.5% com- 
plete after correction for the amount of radioactivity retained in 
wells without cells. Total cellular uptake was determined by mea- 
suring cell lysate radioactivity in a LKB-1282-Compugamma- 
system and was expressed as percent of the applied dose per mg 
cellular protein. The latter was determined using a commercially 
available kit (Biorad, The Netherlands). All activities were cor- 
rected for decay. 
Nuclear binding experiments were performed essentially as 
cellular uptake experiments, asdescribed above, with the follow- 
ing modifications: after incubation, medium was discarded and 
cells were washed twice with ice-cold PBS. Cells were then 
scraped from the wells with a rubber policeman, and resuspended 
in 2 ml ice-cold PBS. Cells were pelleted by centrifugation (300 
g, 4 ° C, 7 rain) and subsequently solubilized in 1 ml PBS, 0.5% 
Triton X-100. After 2 min vortexing, nuclei were spun down (900 
g, 4 ° C, 5 min) and washed twice in PBS, 0.5% Triton X-100. Af- 
ter the final wash, radioactivity of the nuclear pellet was measured 
to determine nuclear binding. 
Data are expressed as mean_+SD for incubations assayed in 
triplicate, with each experiment performed 3-4 times. 
Results 
Figures la  and lb  show the t ime-dependent increase in 
cellular uptake of 99mTc-MIBI, 99mTc-tetrofosmin, 99mTc- 
Q12 and 99mTcO4 -~ both at 37 ° C and 4 ° C in MCF-7 and 
ZR-75 cells. Cell-associated radioactivity, expressed as % 
dose per mg cellular protein, increased with time. It is 
shown that 99mTc-MIBI had the highest cellular uptake, 
fol lowed by 99mTc-tetrofosmin and 99mTc-Q12. At 37°C 
99mTc-MIBI had an uptake of 15.9%+0.5% dose/mg pro- 
tein after 60 rain in MCF-7, and 14.2%___0.4% dose/mg 
protein in ZR-75 cells. 99mTc-tetrofosmin uptake was 
6.8%___0.6% dose/rag protein in MCF-7, and 8.2%_+0.2% 
dose/mg protein in ZR-75 cells and 99mTc-Q12 uptake was 
3.2%_+0.1% dose/rag protein in MCF-7,  and 3.5%+0.3% 
dose/mg protein in ZR-75 cells. Nuclear binding was very 
low: for 99mTc-MIBI, 99mTc-tetrofosmin a d 99mTc-Q12 it 
was less than 0.3% of total cellular binding after 60 rain, 
indicating that nuclear binding did not contribute to total 
cellular uptake of the tested compounds. 
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Fig. 3. Cellular radioactivity of 99mTc-MIBI, 99mTc-tetrofosmin, 
99mTc-Q12 and 99mTcO4- in a MCF-7 cells and b ZR-75 cells af- 
ter zero, one or two washing steps. Cells were incubated with la- 
bel during 60 rain (black bar). After this incubation period, cells 
were washed and incubated for 60 rain with medium without label 
(cross-hatched bar). The whole procedure was repeated once (dot- 
ted bar). lnset: cellular radioactivity after washing, expressed as 
% of the 60 rain uptake 
99mTcO4- was included in this experiment as a nega- 
tive control; cell-associated radioactivity was indeed 
very low and did not show temperature dependence, 
whereas cellular radioactivity of 99mTc-MIBI and 99mTc- 
tetrofosmin was obviously lower at 4 ° C than at 37 ° C. 
99mTc-Q12 uptake showed only slight temperature de- 
pendence. 
Figures 2a and 2b show the time-dependent increase 
in cellular uptake of 99mTc-MIBI, 99mTc-tetrofosmin a d 
99mTc-Q12, at different specific activities, into both 
breast tumour cell lines. It is shown that for all three 
compounds that differences in specific activity in the 
range tested did not influence total cell-associated radio- 
activity. 
Figures 3a and 3b show cellular radioactivity after no, 
one or two washing steps for both breast tumour cell 
lines. Cells were incubated with label for 60 rain. After 
this incubation period, cells were washed twice and in- 
cubated for 60 min with medium without label. The 
whole procedure was repeated once. It is shown that cel- 
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Fig. 4. Cellular radioactivity of 99mTc-MIBI, 99mTc-tetrofosmin 
and 99mTc-Q12, after 60-min incubation, in near-confluent (1.0 
mg/ml cellular protein) and non-confluent (0.3 mg cellular pro- 
tein/ml) MCF-7 cells (a) and ZR-75 cells (b) 
lular radioactivity decreased rapidly after the washing 
procedures. Apart from the differences in cellular uptake 
after 60 min between the compounds, no significant dif- 
ferences were found in residual cellular radioactivity af- 
ter washing between the different compounds when ex- 
pressed as a percentage of their 60 min uptake. 
Figures 4a and 4b show the differences in cellular up- 
take after 60 rain of incubation in cells grown to conflu- 
ence (1 mg/ml cellular protein) and in non-confluent 
grown cells (0.3 mg/ml cellular protein). No differences 
were detected in cellular uptake of 99mTc-MIBI, 99mTc- 
tetrofosmin and 99mTc-Q12 at the various cell densities 
when the uptake was corrected for the amount of cellular 
protein present in the dishes. 
Discuss ion  
99mTc-MIBI, 99mTc-tetrofosmin a d 99mTc-Q12 were all 
introduced for myocardial imaging, but found additional 
applications as they are taken up by different tumours, 
enabling imaging of these lesions in patients [3-8, 11]. 
The studies described here revealed great differences 
in cell-associated radioactivity of human breast turnout 
cells after incubation for 60 rain with 99mTc-MIBI, 
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99mTc-tetrofosmin or 99mTc-Q12. This may have been 
caused by differences in either uptake in or efflux from 
the cell, as cell-associated radioactivity of a radiola- 
belled compound as measured at a certain time point is 
the net result of uptake minus efflux of the compound 
and its metabolites, if any, from the cell. With regard to 
99mTc-MIBI, Chiu et al. [15] have demonstrated that it is 
sequestered within the cytoplasm and mitochondria of 
cultured mouse fibroblasts and that its net cellular reten- 
tion is determined by the electrical potentials across the 
membrane of both the cell and the mitochondria. These 
results suggest hat normal and abnormal tissues with a 
large number of mitochondria per cell show higher 
99mTc-MIBI uptake than tissues with fewer mitochon- 
dria. Investigating the myocellular uptake mechanism of 
99mTc-MIBI in cultured chick myocardial cells, Piwnica- 
Worms and Holman found that the transport of this com- 
pound involves passive diffusion across plasma and mi- 
tochondrial membranes, and that at equilibrium it is 
largely sequestered within mitochondria by the trans- 
membrane potential [16]. Microautoradiography studies 
demonstrated that 99mTc-MIBI is clustered in the area 
around the nucleus. No radioactivity was detectable on 
the plasma membrane and nuclear envelope, in agree- 
ment with the results obtained in this study [17]. As for 
other organs or tissues, the mechanisms of 99mTc-MIBI 
uptake are not precisely known. However, it is likely that 
many factors are simultaneously involved. These include 
the biochemical characteristics of 99mTc-MIBI: its cat- 
ionic charge and lipophilicity, the degree of local blood 
flow, transcapillary exchange, interstitial transport and 
the membrane potential of both mitochondria nd cell 
membranes. 
The exact mechanisms of cellular uptake and reten- 
tion of 99mTc-tetrofosmin and 99mTc-Q12 have not been 
studied, but the same factors as for 99mTc-MIBI may 
play a role. 
As shown in Figures 3a and 3b, we did not find a sig- 
nificant difference in cell-associated activity of 99mTC- 
MIBI, 99mTc-tetrofosmin, 99mTc-Q12 and 99mTcO4- after 
two washing steps, when expressed as a percentage of 
their 60 rain uptake, suggesting that the efflux process of 
the radiolabelled compounds is similar and that the 
quantitative differences in cell-assciated activity are 
caused by differences in uptake. It has recently been re- 
ported that the retention of 99mTc-MIBI also depends on 
the activity of the 170-kPa Pgp coded by MDR1, which 
functions as an ATP-dependent efflux pump for many 
cytotoxic substances, mostly lipophilic cations. 99mTC- 
MIBI is reported to be a ligand for this MDR1 Pgp [9], 
as accumulation of the complex in cells was inversely re- 
lated to the level of Pgp in these cells, and as verapamil 
and cyclosporin A, multidrug-resistant reversal agents, 
enhanced accumulation of 99mTc-MIBI many fold. It has 
been reported that 99mTc-tetrofosmin and 99mTc-Q12 are 
also ligands for the Pgp protein [12, 14]. Functional im- 
aging of Pgp activity may play a role in chemotherapy 
regimens for maximal benefit of the patient. The detec- 
tion of tumours which have Pgp-mediated resistance is 
important o prevent he patient being exposed to toxic 
chemotherapy which is not likely to be effective. 
As it has been reported that diffusion plays a role in 
uptake through the plasma membrane, we also investi- 
gated the influence of cell density in the wells using 
breast umour cells that were either used when grown to 
confluence (1 mg/ml cellular protein) or when grown 
non-confluent (0.3 mg/ml cellular protein). Although it 
may be supposed that in the case of non-confluent grown 
cells more plasma membrane area is available for diffu- 
sion than in tightly confluent grown cells, under the con- 
ditions used in our study this did not influence cell-asso- 
ciated radioactivity after 60-rain incubation (Fig. 4). 
To investigate whether the differences in cellular up- 
take could be explained by differences in the specific ac- 
tivity of the labels used, we performed studies in the 
breast cell lines with different ~pecific activities of each 
compound (Fig. 2). On a molar base, the difference be- 
tween the highest (MIBI) and lowest (tetrofosmin) com- 
pound mass per kit is by about a factor of 10. As shown, 
however, tenfold differences in specific activity did not 
influence the cell-associated radioactivity of the three ra- 
diolabelled compounds. 
In these experiments, data are expressed as % 
dose/rag cellular protein. It appeared that differences in 
uptake of the tested compounds did not change when up- 
take was expressed as % dose/~g DNA (not shown), 
which cancels differences introduced by variations in 
cell sizes from culture to culture. 
From our experiments it can be concluded that of the 
Tc-labelled compounds tested, 99mTc-MIBI has the high- 
est cellular uptake during 60 min in both human breast 
tumour cells, theoretically making it the most suitable 
compound for imaging. However, it has been reported 
that when 99mTc-tetrofosmin was compared with 99mTc- 
MIBI in a 1-day, rest and dipyridamole stress myocardial 
single-photon emission tomographic maging setting, no 
significant differences were observed in the quality or 
the diagnostic interpretation of the images [13]. In vivo 
not only radioactivity in the target organ is important for 
imaging, but also the ratio of radioactivity in the target 
versus that in the background. The extensive hepatobili- 
ary excretion of 99mTc-MIBI and its localization in heart, 
liver, kidneys and total gastrointestinal tract [10] may 
have contributed to the aforementioned finding. The bio- 
distribution of 99mTc-MIBI also poses a problem for im- 
aging in the abdomen, and the reported advantageous 
pharmacokinetics in vivo of 99mTc-tetrofosmin over 
99mTc-MIBI for cardiac imaging [13] may also apply to 
tumour imaging. Therefore, further studies in vivo need 
to be performed to identify the optimal imaging agent. 
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